Orion Corporation’s publication schedules for financial reporting in 2017

ORION CORPORATION      STOCK EXCHANGE RELEASE 19 JULY 2016 at 11:00 a.m. EEST              


Orion Corporation's publication schedules for financial reporting in 2017


Orion Corporation will publish its Financial Statement Release 2016 on Wednesday, 8 February 2017.

The publication dates of the Interim Reports and the Half-Yearly Report in 2017 are as follows:

Interim Report January-March 2017                     Wednesday, 26 April 2017
Half-Yearly Report January-June 2017                Wednesday, 19 July 2017
Interim Report January-September 2017              Thursday, 26 October 2017

The Financial Statements and the report of the Board of Directors 2016 will be published on the Company's website at the latest in week 9/2017.

The Annual General Meeting is planned to be held on Wednesday, 22 March 2017 in Helsinki.

Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases. 

  
Orion Corporation

Timo Lappalainen
President and CEO
  Olli Huotari
SVP, Corporate Functions
 

                                                                       
Contact person:
Tuukka Hirvonen, Communications Manager, financial communications and investor relations
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02101 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2015 amounted to EUR 1,016 million and the company had about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki..

HUG#2029310

Ads